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Abstract
We need to find ways of enhancing the potency of existing antibiotics, and, with this in mind,
we begin with an unusual question: how low can antibiotic dosages be and yet bacterial
clearance still be observed? Seeking to optimise the simultaneous use of two antibiotics,
we use the minimal dose at which clearance is observed in an in vitro experimental model of
antibiotic treatment as a criterion to distinguish the best and worst treatments of a bacteri-
um, Escherichia coli. Our aim is to compare a combination treatment consisting of two syn-
ergistic antibiotics to so-called sequential treatments in which the choice of antibiotic to
administer can change with each round of treatment. Using mathematical predictions vali-
dated by the E. coli treatment model, we show that clearance of the bacterium can be
achieved using sequential treatments at antibiotic dosages so low that the equivalent two-
drug combination treatments are ineffective. Seeking to treat the bacterium in testing cir-
cumstances, we purposefully study an E. coli strain that has a multidrug pump encoded in
its chromosome that effluxes both antibiotics. Genomic amplifications that increase the
number of pumps expressed per cell can cause the failure of high-dose combination treat-
ments, yet, as we show, sequentially treated populations can still collapse. However, dual
resistance due to the pump means that the antibiotics must be carefully deployed and not
all sublethal sequential treatments succeed. A screen of 136 96-h-long sequential treat-
ments determined five of these that could clear the bacterium at sublethal dosages in all
replicate populations, even though none had done so by 24 h. These successes can be at-
tributed to a collateral sensitivity whereby cross-resistance due to the duplicated pump
proves insufficient to stop a reduction in E. coli growth rate following drug exchanges, a re-
duction that proves large enough for appropriately chosen drug switches to clear
the bacterium.
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Author Summary
So-called “cocktail” treatments are often proposed as a way of enhancing the potency of
antibiotics, based on the idea that multiple drugs can synergise when used together as part
of a single combined therapy. We investigated whether any other multidrug deployment
strategies are as effective as—or perhaps even better than—synergistic antibiotic combina-
tions at reducing bacterial densities. “Collateral sensitivities” between antibiotics are fre-
quently observed; this is when measures taken by a bacterium to counter the presence of
one antibiotic sensitise it to the subsequent use of another. Our approach was to see if we
could exploit these sensitivities by first deploying one drug, then removing it and instead
deploying another, and then repeating this process. This is not an entirely new idea, and
there is a precedence for this form of treatment that has been trialled in the clinic for Heli-
cobacter pylori infection. The idea we pursued here is an extension of “sequential treat-
ment”; we investigated whether with two antibiotics and n rounds of treatment, if we
search within the set of all possible 2n “sequential treatments”—including the two single-
drug monotherapies—there might be treatments within that set that are more effective
than the equivalent two-drug cocktail. Using a simple in vitro treatment model, we show
that some sequential-in-time antibiotic treatments are successful under conditions that
cause the failure of the cocktail treatment when implemented at the equivalent dosage.
Introduction
Bacteria have a remarkable capacity to adapt and evolve. It is probably unsurprising in retro-
spect that resistance has developed to every antibiotic in clinical use [1], with the genes respon-
sible disseminated globally [2,3]. Antibiotic resistance, therefore, has the potential to become a
very grave problem. Bacteria evolve so rapidly, in fact, that whole-genome sequencing studies
have been able to elucidate dozens of de novo drug-resistance mutations occurring at high fre-
quency within a clinical patient’s infection during a 12-wk treatment [4]. Given this, the follow-
ing seems an important question: what ways of combining antibiotics might be used to combat
infection even when the bacterial species in question exhibits rapid decreases in drug suscepti-
bility during treatment? Or, to put it differently, how can we enlarge the “optimisation space”
of antibiotic combinations and search within those for novel, effective treatments?
One possibility may lie with so-called sequential treatments. They have been the subject of
several recent laboratory studies [5–7] and clinical trials [8,9] in which the idea is to alternate
the use of different antibiotic classes through time. Thus, if, for example, two antibiotics are
available and n rounds of treatment are to be given, then there are 2n different ways of adminis-
tering the drugs. Our hypothesis states that this exponentially large optimisation space can
contain more effective treatments than the equivalent two-drug combination treatment when
the same dosages of each antibiotic are applied.
We demonstrate the veracity of this claim in one particular in vitro laboratory model that
mimics something of the gravity of the situation we now face by using a bacterium that pos-
sesses a scalable drug efflux mechanism that quickly reduces the efficacy of the antibiotics at
our disposal. Despite this mechanism, we show that sequential treatments can clear the bacteri-
um when the equivalent combination treatment fails to, provided, that is, that the drugs are de-
ployed in a suitably optimised, sequential manner.
To demonstrate this, we use the following laboratory system. Escherichia coli K12 (AG100)
is targeted with two antibiotics, erythromycin (a macrolide, ERY) and doxycycline (a tetracy-
cline, DOX), that bind to different ribosomal RNA subunits, thereby inhibiting translation.
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While this is a nonclinical drug pairing, the commercial drug Synercid (comprising quinupris-
tin and dalfopristin) also targets ribosomal RNA combinatorially [10]. Moreover, some clinical
combinations have ambiguous pharmacological interactions that can appear antagonistic in
vitro [11,12], whereas the ERY—DOX pairing has an established synergy [13,14].
Before continuing, we need to declare a standard notational device that we will use through-
out. It defines how antibiotic efficacy is measured, independently of the drug under study.
Thus, ICx will denote the antibiotic concentration that reduces the density of the ancestral bac-
terial strain (AG100), rather than (for example) any other fitness measure, exponential growth
rate, or area under a growth curve, by a factor x% relative to that produced without antibiotic
in any single period of bacterial growth.
Now, E. coli is known to decrease susceptibility to ERY and DOX by amplifying a genomic
region that contains the operon acrRAB because a multidrug pump is formed from the prod-
ucts of acrRAB and tolC [13,15]. Selection for amplification mutations occurs even when the
drugs are combined at high concentrations whereupon pump duplications and triplications are
observed [16]. The triplications permit bacteria subjected to 5 d of combination treatment at
twice IC95 dosages, and thus at very low population densities, to eventually restore their growth
rates and population densities to almost untreated levels [16].
In these circumstances, the successful clearance of E. coli using sublethal dosages of ERY
and DOX appears implausible. Low-dose monotherapies are unlikely to work [17], and com-
bining the antibiotics into a synergistic IC50 cocktail (that achieves IC90 overall because of the
synergy) is known to be futile because of resistance increases provided by the pump duplica-
tions [13]. We therefore turn to sequential treatments, an approach that has been used to treat
cancers [18–20] and some clinical infections [9]. These might also appear predestined to fail;
after all, cross drug collateral sensitivities are believed to be the basis of successful sequential
treatments [7], whereas our model system, by contrast, has a scalable multidrug pump at
its disposal.
Nevertheless, to evaluate the impact of extended antibiotic treatments, we propagated popu-
lations of E. coli in 96-well microtitre plates containing liquid medium supplemented with anti-
biotics based on 12-h cycles, aka seasons, of growth. Thus, two drug treatments per day were
administered. At the end of each season, 1% of the spent liquid media, containing biomass, was
transferred to a plate containing fresh medium and antibiotics, where growth could resume.
The media was supplemented with enough glucose that this protocol would not clear the bacte-
rium in the absence of drug but would instead establish a near-constant, season-by-season
total observed population density of about 108 cells per ml in stationary phase (as can be dis-
cerned from Fig S1 and Fig S7 in S1 Text). Given this model, we sought antibiotic treatments
capable of clearing the bacterium.
Results
Low-Dose (IC50) and Mid-Dose (IC70) Sequential Drug Screens
By the term sequential treatment, we mean the following protocol: one of the two drugs is used
in season 1, and, whether ERY or DOX, it may be re-used in season 2, or, alternatively, the
other drug may be deployed instead. This process then continues each season until treatment
ends. For a treatment of eight seasons, there are 28–2 = 254 possible sequential protocols
(minus the two monotherapies). However, seeking to understand whether drug switches per se
reduce population growth, only balanced sequential treatments that use four seasons of both
drugs were trialled (Fig S6 in S1 Text, section 1). Seeking evidence of successful low-dose treat-
ments, we first treated E. coli with ERY and DOX for eight seasons at dosages corresponding to
the IC50 of each drug, implementing the following treatments: two monotherapies, one 50/50
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combination using a half dose of both drugs (achieving approximately IC90, Fig S3 and Fig S4
in S1 Text, section 1) in addition to 70 sequential treatments (three replicates each). An analo-
gous screen of sequential treatments was then implemented at IC70 dosages (but only 66 of
these sequential treatments were implemented).
Fig. 1 summarises the IC50 data. In Fig. 1A, the 50/50 combination treatment achieves great-
er single-season inhibition than each monotherapy, as expected from prior reports of synergy
(p<10-7, test as indicated in Fig S3 in S1 Text). However, by 36 h the combination therapy no
longer produces the lowest bacterial densities, and by 96 h it produces high final densities
(Fig. 1A and Fig. 1B), higher than the mean of the family of sequential treatments (p<10-8,F
(1,69)!47.1, one-way ANOVA). Although a sequential treatment has the lowest final density
of all those trialled (Fig. 1A), no IC50 treatment provided any evidence of eliminating the bacte-
ria by 96 h.
After increasing dosages to their IC70 values, the following evidence of bacterial clearance by
96 h was observed. Sixteen sequential treatments that produced some of the lowest population
densities after 96 h of treatment (treatments marked with boxes in Fig. 2A) were examined,
and, using spot tests, we could isolate no live cells for five of these treatments in all three repli-
cates. The 11 remaining treatments lead to a zero cell count in some replicates but not in all
(Fig S15 in S1 Text, section 3). We then replicated all 16 treatments an additional three times,
and the five previously successful treatments again produced a zero cell count by 96 h, although
the remaining 11 treatments showed substantial between-replicate variability in their popula-
tion dynamics (Fig S15). By contrast, Fig. 2B shows that the 50/50 combination treatment
(with a greater inhibition than IC70 due to the synergy) and both monotherapies yielded recov-
ering (i.e., increasing) mean population densities beyond 48 h at these dosages. (In addition,
we recall that twice IC95 combinations of these drugs can fail in this treatment model too [16].)
However, these observations serve to illustrate that appropriately optimised, sequential thera-
pies at IC70 can clear a bacterium even when synergistic combination treatments with greater
one-season inhibition do not.
In order to determine genetic changes due to the differential stresses found in drug-free con-
ditions and in the sequential and combination treatments, two treatments at IC50 that pro-
duced comparable densities at 96 h were subjected to a whole-genome sequencing analysis and
compared to the drug-free populations (S1 Text, section 4). Writing “E” for a season of ERY
and “D” for DOX, when metagenomes from the EDEDEDED and 50/50 combination treat-
ments were sequenced, known resistance mutations were observed in both. Fig. 3B highlights a
412 Kb genomic region containing the acrRAB operon whose duplication was observed more
frequently in both the combination and sequential treatments at 96 h (namely, eight seasons)
than at 24 h (or two seasons; Fisher exact test for both, p = 0.05; Fig S17 in S1 Text, section 4).
Treating sequentially does not, therefore, avert selection for duplications of the
acrRAB operon.
We sought evidence for triplications of acrRAB by asking whether the ratio of coverage
depths between amplified and nonamplified genomic regions was above a value of 2, the latter
being the maximum value possible of this statistic if no triplications were present. However, at
96 h, in neither the sequential treatment (one-sided t test, p!0.12,T!1.68,n = 3) nor the 50/50
combination treatment (one-sided t-test, p!0.061,T!2.60,n = 3) was this value significantly
above 2. Finally, single nucleotide polymorphisms (SNPs) were observed in the putative drug
transporter genemdtG (yceE [21]) in all conditions (Table S3 in S1 Text, section 4); this mem-
ber of themarA-soxS-rob stress regulon mediates expression of the acrAB-tolC pump [22].
We expected the rate of adaption (defined as a rate of increase in growth rate [14]) to corre-
late positively with dose. Instead, we observed that adaptation can be just as rapid in the ab-
sence as in the presence of antibiotics (Fig. 3A), and our culture conditions may explain this.
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Slow growing cells, like persister phenotypes [23] and small colony variants [24], are cleared by
our protocol, whereas cells that achieve rapid growth above approximately 6.6 generations
every 12 h can survive. Rapid bacterial growth is associated with physiological changes that in-
clude negative DNA supercoiling and multiple DNA replication forks per cell [25], increased
cell size [26], and heightened ribosomal demand [27]. The latter likely induced a stringent re-
sponse in the fastest growth conditions (the absence of drug). In these conditions, SNPs associ-
ated with fatty acid degradation, lipid peroxidation stress, and sulphur transportation (tauA)
were observed, the latter at high frequency (Table S3 in S1 Text, section 4). As tauA is express-
ed in our growth media only during cysteine limitation [28], overcoming α-amino acid starva-
tion is a likely mechanism supporting the SNPs detected in all seven 23S ribosomal RNA
operons (rrn) of E. coli by 96 h in the absence of drugs (Table S1 in S1 Text, section 4). Al-
though mutations in the same rrn loci were observed at low frequency at 96 h in the slower-
growing populations treated sequentially with drugs, none of these operons were mutated in
populations treated with the drug combination. We hypothesise, therefore, that the antibiotics
have slowed the rise and sweep of adaptive mutations needed for optimal growth in our culture
conditions (Table S1 in S1 Text, section 4). Finally, we found no significant evidence of SNPs
within drug targets in any conditions (S1 Text, section 4).
Fig 1. At IC50 dosages, population recovery is fastest for the 50/50 combination treatment and slowest
for a sequential treatment. (A) Mean densities are shown at the end of each season for all sequential
treatments at IC50 (as blue and green dots) and for the 50/50 combination of both drugs (black dotted line).
The treatment maximising inhibition in season 1 (at 12 h) is the 50/50 combination treatment, because of the
synergy. However, by season 8 (at 96 h), all sequential treatments produce lower mean densities than the 50/
50 treatment, out of which the lowest density obtained from all the treatments tested is indicated by red
circles. Also shown are mean final densities (see x-label “means”) of the 50/50 treatment (black circle), the
best sequential treatment (red circle), and of all sequential treatments (green circle ± SE, three replicates per
treatment). (B) A forest plot showing densities obtained using different sequential treatments at 96 h relative
to the 50/50 treatment (drug orders are illustrated by the blue and green boxes on the left). The vertical black
line represents the mean density for the 50/50 combination, the vertical dashed line is the mean of all the
sequential treatments, and the dots mark the deviation in density produced from the 50/50 combination
treatment (± SE, n = 3). Like (A), this shows that the combination treatment performs at the poorest extreme
of the distribution of all sequential treatments measured in terms of how bacterial growth is suppressed by 96
h. There is no evidence of bacterial clearance in any treatment. (S1 Data contains the data used in this
figure.)
doi:10.1371/journal.pbio.1002104.g001
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Nonreciprocal Collateral Sensitivity
Antibiotic combinations are used to slow drug-resistance adaptation because they enhance
their antibacterial effect through inhibitory synergisms [29] and because they reduce the num-
ber of potential resistance mutations. Here, consistent with prior studies of ERY—DOX combi-
nations [13], growth rate adaptation is so rapid when using ERY and DOX in a synergistic IC70
combination that the bacterium is not cleared (Fig. 1A, Fig. 2B, Fig. 3A), and an analogous ob-
servation has already been made at double IC95 dosages [16].
Collateral sensitivities on the other hand, in which the prior use of one antibiotic sensitises
the bacterium to the use of another, have few recognised mechanisms [30], but they too have
been proposed as a possible basis for successful sequential treatments [7,31] because the change
Fig 2. Some examples of successful sequential treatments at IC70 dosages. (A) This Manhattan plot at IC70 shows the mean total optical densities
observed during eight seasons of treatment (Σ0D(T) on the vertical axis, vertical lines are SE, and n = 3). Note the 16 treatments marked with a red or black
square: they had among the lowest final densities of the treatments trialled. After this, the 16 treatments were replicated; a red square shows that a zero cell
density was observed in all three initial and subsequent replicates of that treatment, and black squares show a zero population density was observed in
some, but not all, replicates. (B) The no-drug, ERY, and DOXmonotherapies and the 50/50 combination treatment all produce recovering mean population
densities at IC70 doses. These four unsuccessful treatments are shown next to the optical density dynamics of three replicates of a successful “red square”
treatment from (A) (treatment C in panel C). The three replicates (shown as grey lines with blue [DOX] and green [ERY] circles) indicate parallel dynamics
and fluctuating decay towards zero (bars are SE of optical density at 96 h, n = 3). (C) Season-by-season mean densities of all the successful (red square)
treatments from (A); note how two achieve high densities early during treatment. Fig S15 in S1 Text, section 3, shows colony-forming units for replicates of
these treatments. (S1 Data contains the data used in this figure.)
doi:10.1371/journal.pbio.1002104.g002
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of environment hampers adaptation. Promisingly, the rate of adaptation is demonstrably lower
here for sequential treatments than for combinations (Fig. 3A; p<10-4,F(2,21)!16.8, one-way
ANOVA with Bonferroni correction). However, it has also been suggested that the antibiotic
sequences should follow optimised pathways through networks of drug choices that maximally
Fig 3. The rate of adaptation has a complex relationship with antibiotic dose. (A) Using IC50 dosages, growth rate adaptation (denoted α when defined
in [14]) is greater for the 50/50 combination than for the EDEDEDED (“ERY—DOX”) and DEDEDEDE (“DOX—ERY”) sequential treatments. Adaptation can
also be faster in the absence, rather than in the presence, of antibiotics. The right-hand plot shows each replicate separately (as a dot), indicating treatment
clusters as coloured regions using the convex hulls of the datasets for each treatment type (whether no drug or single drug monotherapies, the 50/50 two-
drug combination, or a sequential treatment). This shows sequential treatments minimise both final growth rate after eight seasons and the rate of adaptation.
(B) Differences in the rate of adaptation in (A) are not accounted for by the duplication of the acrRAB operon, and sequential treatments do not prevent pump
duplications. These coverage plots from sequenced populations at 24 h and 96 h show that both the combination (50/50) and sequential treatments (ERY/
DOX) lead to the duplication of a genomic region from 273 Kb to 686 Kb that contains acrRAB. Left: the duplication was absent from all treatments after 24 h.
Right: the duplication (the dark sector) is present in both the 50/50 combination and ERY—DOX sequential treatments after 96 h, but not in the no-drug
control. Single nucleotide polymorphisms (SNPs) are highlighted as arrowheads next to the treatment in which they were observed. (S1 Data contains the
data used in this figure.)
doi:10.1371/journal.pbio.1002104.g003
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sensitise the bacterium to treatment [7]. However, E. coli AG100 has pumps for both ERY and
DOX, and we might therefore expect to observe cross-resistance, not collateral sensitivity, for
this drug pair and this bacterium [6]. It therefore appears we do not have enough drugs for
drug cycling to work in this model, but it will turn out, in fact, that we do.
This is because at least two cross sensitivity properties are observed. The first of these,
which was noted recently for doxycycline [6], we term nonreciprocal collateral sensitivity
(NCS), and it is defined as follows. Label two drugs “A” and “B” and choose equivalent dosages
for both, meaning ICx for some x, and let D(T1,T2) denote density of the population when
treatment T2 follows treatment T1. We will also use the notation A
n and Bn to denote mono-
therapies with n rounds of treatment. Now, suppose we begin with a clonal population and
treat with A for n+1 time units so that D(An,A) denotes the population density after the (n+1)-
th treatment. Then, in a separate experiment, we treat with A for n time units followed by B for
one time unit so that D(An,B) denotes the final population density. A nonreciprocal collateral
sensitivity between A and B is said to occur when the switch from A to B results in a density de-
crease so that D(An,B)<D(An,A), whereas an analogous switch from B to A results in a density
increase, meaning D(Bn,A)>D(Bn,B). When satisfied, this definition means A-adapted popula-
tions appear sensitised to drug B, whereas B-adapted populations have increased resistance to
A.
If present, an NCS demonstrates that single-season inhibitory values cannot be used to infer
the later inhibitory effect of antibiotics as the treatment proceeds; thus, ICX values and rate of
adaptation measures capture very different properties of the bacterium. For example, despite
both drugs having equivalent inhibitory effects on a wild-type population after one dose, drug-
resistance mutations could sweep more rapidly for one drug than the other, and this could re-
sult in an NCS. Nevertheless, if the observed collateral sensitivity is much larger than the cross-
resistance within a dataset that indicates the presence of an NCS, appropriately chosen sequen-
tial regimens may still be sufficiently potent to eliminate the bacterium.
Postulating a Mechanism That Supports Nonreciprocal Collateral
Sensitivity
We first sought collateral sensitivities within the entire dataset shown in Fig. 2A but found no
significant evidence (Fig S12 in S1 Text, section 3) that a switch from ERY to DOX had a differ-
ent effect on population density than switching from DOX to ERY. We therefore tested for the
presence of an NCS using a simpler “(n+1)-protocol”: n seasons of culture with one drug, fol-
lowed by a switch to the other drug for just one season’s duration. This protocol (Fig. 4) shows
that when AG100 is treated with ERY for n seasons (of 24 h duration) and DOX on the (n+1)-
th season, both at IC70, the continued increase in bacterial density on the last season is consis-
tent with cross-resistance (see Fig. 4B for p-values). However, when treating with DOX for n
seasons and then ERY on the (n+1)-th, a density reduction is observed on the last treatment,
consistent with a collateral sensitivity (Fig. 4B). This drug pair therefore possesses an NCS: al-
though both inhibit growth of wild-type E. coli equally, they report different levels of inhibition
on drug-adapted populations.
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This observation accords with predictions of the following theoretical model [13]:
d
dt
b1 ¼ GðS;D1;E1Þb1 % dðb1 % ð1þ DÞb2Þ; ð1Þ
d
dt
bj ¼ GðS;Dj;EjÞbj % dðð2þ DÞbj % bj%1 % ð1þ DÞbjþ1Þ; ð2Þ
d
dt
bN ¼ GðS;DN ;ENÞbN % dðð1þ DÞbN % bN%1Þ; ð3Þ
d
dt







Dext ¼ %dDDext %
XN
j¼1
















Eext ¼ %dEEext %
XN
j¼1














where j = 2,. . .,N-1 is a parameter that controls the number of efﬂux genes each cell can
Fig 4. A nonreciprocal collateral sensitivity at IC70 dosages with respect to population densities. (A)
The concentration of each drug was calibrated to ensure IC70 was achieved for both drugs, here at 18 h. (B) A
nonreciprocal collateral sensitivity (NCS) determined using the (n+1)-protocol described in the text, where n =
3,4,. . .,7: the change in densities following a change in antibiotic demonstrates ERY! DOX cross-resistance
but DOX! ERY cross sensitivity (p-values from t tests, n = 5). (S1 Data contains the data used in this figure.)
doi:10.1371/journal.pbio.1002104.g004
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express. Equations 1–8 capture the densities, bj, of bacteria with duplications of a gene that ex-
ports drugs from within the cell. At time t, S is the concentration of a limiting carbon source,
Dext and Eext are extracellular concentrations of each drug, DOX and ERY respectively, Dj and
Ej are the intracellular drug concentrations, and drugs degrade at rates dD and dE. The variable
pj represents the expected number of efﬂux pumps expressed by a cell with j-1 efﬂux genes, for
each j'2. We also assume that p1 = 0 so that it is possible for cells to encode the pump without
expressing it (meaning genotypes for which j = 1 have the efﬂux gene but do not express it).
More generally, the nonzero quantity pj+1 is deﬁned, for j'1, by j/(1+γ(j)), and then pj/(ke+pj)
is the probability that a given drug molecule is bound to an efﬂux pump. This model is a sim-
pliﬁcation of the competition each transcription unit has for each efﬂux operon (the acrRAB
promoter), whereby a diminishing return is present in the number of pumps expressed as the
number of efﬂux genes increases; the rate of diminishing returns is controlled by γ>0. In-
creases and decreases in the number of efﬂux genes in a cell are assumed to be a Poisson pro-
cess with parameter δ per cell per hour.
Other variables in Equations 1–8 have the following meaning: φe,φd are antibiotic diffusion
rates across the cell membrane, νe,vd are maximal drug efflux rates, and ke,kd are half-saturation
constants associated with pump-antibiotic binding; V and K are maximal uptake rate and half-
saturation constants associated with a Michaelis-Menten uptake model of the limiting carbon
source (S); growth rate G(S,D,E) = cVS/((1+keE+κdD+κedED)(K+S)) is proportional to uptake
rate via a per-sugar biomass yield constant c, and G(S, D, E) is reduced in value synergistically
by the drugs (where κe,κd and κed are parameters that control drug efficacy and strength of syn-
ergy); δ is the rate of amplification of the efflux gene, and δ(1+Δ), a value necessarily greater
than δ, is the rate of loss of the gene. N-1 is the maximum number of copies of the efflux gene.
We set N = 3 to represent three different cell phenotypes: an unexpressed pump gene (a wild
type), a single expressed pump gene, and one additional copy of that gene in which both copies
are expressed. Finally, the model is simulated with several seasons so as to mimic the in vitro
protocol, with the loss of 99% of all cells implemented at the end of each season. Equations 1–8
were solved numerically using a parameterisation determined from a prior training dataset (S1
Text, section 5) [13].
Although our theory does not capture all aspects of our data, computations show that, like
E. coli, the model possesses an NCS (Fig. 5). The model predicts that a pump asymmetry due to
different efflux efficiencies of ERY and DOX produces populations with differential susceptibil-
ity to each drug resulting from having different frequencies of drug-susceptible wild-type cells
existing in mutation-selection equilibrium with less susceptible mutants (Fig. 5A). Supporting
the hypothesis of different efflux efficiencies of ERY and DOX, data from the E. coli acr efflux
knockout strain AG100A(Δacr) (Table S2) [13] shows that the loss of acrB reduces the IC50 of
ERY to approximately 5% of the wild-type AG100 value but reduces it to just 23% in the case
of DOX. The model captures others features of the data, particularly that appropriately chosen
sequential treatments produce fewer bacteria than the combination, yet some sequential treat-
ments produce more (Fig S18 in S1 Text, section 5).
A second cross sensitivity property of the ERY—DOX was also established, as follows. Hav-
ing found a mechanism for an NCS with respect to population densities, we hypothesised that
the (n+1)-protocol data could exhibit cross sensitivities with respect to other measures of bac-
terial fitness. To demonstrate this, we fitted the logistic growth model dxdt ¼ R ( xð1% x=KÞ to
bacterial density time series, where the parameter R is per hour per capita growth rate and K is
the population carrying capacity. The resulting data exhibits collateral sensitivities irrespective
of the order in which the drugs were exchanged because a reduction of R was observed
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following a change of drug for every n tested (from 3 to 6), although not all reductions were sig-
nificant (Fig. 6).
Discussion
Despite the ability of bacteria to adapt to an antibiotic challenge, our laboratory model shows
that one can exploit a sensitising property of fluctuating environments to eliminate a bacterium
eventually at dosages that only inhibit growth by 70% initially. However, ours is a very simple
treatment model inspired by bacterial infections, and we do not wish to overstate its predictive
power in relation to the treatment of humans. In particular, the loss of slow-growing cells from
our microcosm is not representative of the in vivo conditions in which slow-growing, antibiot-
ic-tolerant phenotypes can be responsible for recalcitrance to treatment [32]. Our model is also
limited because it lacks an immune response or any of the environmental complexity found in
the human body.
The clinical practise of how antibiotics are used to treat bacterial infections begins with the
minimal inhibitory concentration (MIC), the minimal drug concentration at which no visible
growth of a bacterium is observed after overnight culture in vitro [33,34]. After determining
the MIC, antibiotics are deployed at high enough dosages so that peak concentrations are
achieved in vivo well in excess of this number [35]. Experience has shown that super-MIC dos-
ages are necessary for successful recovery from infection when using combination treatment
and monotherapy [33–39], although there is recent evidence of effective lower-dose antifungal,
anti-MRSA (methicillin-resistant Staphylococcus aureus), and antimalarial treatments in vivo
[40–42]. However, so few sequential treatments have been trialled in the clinic that there is little
accumulated data on or understanding of what dosing or scheduling criteria might be needed
when using sequential treatments in vivo.
Furthermore, not all IC70 sequential treatments lead to clearance, and some drug sequences
produced higher population densities than the equivalent combination treatment (Fig. 2A).
Fig 5. A mathematical model indicates frequency-dependent selection for the pump duplication can cause a nonreciprocal collateral sensitivity
profile with respect to population densities. (A) The first two columns indicate modelled internal drug concentrations in three cell phenotypes (dark blue:
“wild-type” cells not expressing the pump; red: the pump gene is expressed; dark grey: two pump genes are expressed). The third column shows modelled
population densities through time, indicating the frequencies of each phenotype within that density. The different drugs select for resistant (pump-expressing)
and susceptible (pump-not-expressed) phenotypes at different rates, despite both having been calibrated to equal inhibitory effect (namely IC50) on a
population consisting almost exclusively of wild-type cells by the end of day 1. These simulations show that monotherapies consisting of either drug select for
different population structures, each having different frequencies of the pump gene and its duplication, depending on which drug is being applied. Thus, given
5 d of adaptation to DOX followed by adaptation to ERY, after the switch, density decreases. (B) Implementing the (n+1) protocol in the model is consistent
with the data of Fig. 4. (S1 Data contains the data used in this figure.)
doi:10.1371/journal.pbio.1002104.g005
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The reasons for this are not clear, although both data and the theoretical efflux model do exhib-
it large between-treatment variation (Fig. 2A, Fig S18 in S1 Text, section 5). A prior hypothesis
states that greater antibiotic heterogeneities in the bacterial environment should diminish the
rate of drug-resistance adaptation [43]. This would mean, for example, that bacteria adapt
more readily to an EEEEDDDD treatment (one drug switch) than to EDEDEDED (seven
switches). We therefore sought a relationship between bacterial population densities and the
number of drug switches implemented in different sequential treatments but found no evi-
dence of the predicted correlation (Fig S11 in S1 Text, section 3).
It is well known that the use of low dosages can select for resistant strains when they are
competed in co-culture with susceptible strains [17]. However, that mid-dose clearance is still
possible has a simple explanation in principle: the antibiotic sequences eventually reduce, and
then maintain, Malthusian fitness of the evolving population below zero. To examine this in
the simplest of theoretical contexts, suppose Bn represents bacterial population density after n
rounds of treatment where 1-I, with 0<I<1, is an expected fraction of cells that are not cleared
by the treatment but instead lost because of other effects (for example, host immunity) each
Fig 6. A collateral sensitivity at IC70 with respect to per capita growth rate, R. (A) Optical density time
series data used in Fig. 4 was reused by fitting a logistic growth model (defined in the text) to estimate growth
rates. For clarity, both the growth rate parameter R and the regression coefficient R2 from exemplar fits are
indicated alongside modelled dynamics. (B) The resulting dataset shows significant and nonsignificant
collateral sensitivities with respect to growth rate (R) following an exchange of antibiotic (t tests, n = 5). (S1
Data contains the data used in this figure.)
doi:10.1371/journal.pbio.1002104.g006
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treatment. Indeed, granulocyte-mediated clearance has been shown to achieve a two-log10 re-
duction in bacterial load in a 24 h period using a murine model [44], giving a value of I!1/100.
At any sublethal dosage, whereby exponential population growth (at rate r) occurs between
treatments spaced T time units apart (cf. Fig. 1A), it follows for a bacteriostatic antibiotic at a
dose of “A units” that Bn+1 = I(Bne(r-A)T. Bacterial clearance is assured when the population de-
cays eventually; this happens when Bn+1/Bn<1, which is equivalent to the condition A>r-(log
(I-1))/T. Note that this value is less than r by an amount that depends on I. If we now define an
analogy of the MIC as, say, the IC99 in this toy model, which is the antibiotic dose that reduces
bacterial growth by 99% after one treatment, the condition on A to achieve IC99 is e
(r-A)T<1/
100, or A>r+(log 100)/T. This value is greater than r and therefore effective therapeutically,
but it is not representative of the critical minimal dose needed to clear the bacterium [45].
The absence of visual eradication overnight in vitro should not, according to this argument,
itself be used as a rationale to preclude the practical use of an antibiotic drug. Indeed, the anti-
fungal azole drugs are used to treat Candida albicans clinically at dosages that do not always
eliminate population growth after overnight culture in vitro [45–47]. In our in vitro study, we
needed to keep the rate of adaptation low for the above theoretical rationale to work, and only
certain sequential treatments were able to do this (Fig. 3A and 3B). The requirement for low
rates of adaptation likely needs the mutations and physiological changes that arise early during
treatment, when population sizes are large, to provide no benefit, or even be deleterious later
during treatment and so prevent recovery when population size, and mutational supply,
is small.
There have been clinical successes for one particular sequential treatment:Helicobacter pylo-
ri infection has improved eradication rates for a sequential treatment relative to a combination
therapy at the same dose [8,9], although geographical variations in successes have been ob-
served and attributed to pathogen strain differences [48]. We hypothesise that the treatment of
other clinical pathogens may be possible using sequential antibiotic treatments.
We note that low dosing is used to treat some bacterial infections. The ability of antibiotics
to act as modulators of gene expression at low doses [49] can be exploited, for example when
certain drug classes (including macrolides) are used to control the expression of virulence fac-
tors in MRSA [50]. Moreover, the use of β-lactam antibiotics as a low-dose adjuvant is a novel
strategy in the treatment of recalcitrant MRSA infection [51,52], even though MRSA is resis-
tant to most of these drugs. The β-lactam does not target the cell directly; rather, it enhances
the activity of host peptides that are not antimicrobial per se but which modulate the host im-
mune response [53].
However, it is not our intention to advocate for the indiscriminate clinical use of low-dose
regimens. Rather, we are claiming that sequential dosing strategies exist for administering anti-
biotics that are sufficiently potent, and which prevent adaptation enough, to clear a bacterium
when the equivalent dose combination treatment fails to do so. That this can be done even
though the bacterium has a scaleable multidrug resistance mechanism in its chromosome gives
us cause to hypothesise that new ways of optimising antibiotic use in vivo can be found by al-
ternating them as part of treatment.
Materials and Methods
Media and Strains
We used E. coli AG100 (a gift from Stuart B. Levy) and M9 minimal media (0.2% glucose and
0.1% casamino acids). Stock solutions of DOX and ERY were made from powder stocks
(Sigma-Aldrich) at 5 mg/ml in water for DOX and 100 mg/ml in ethanol for ERY and stored at
-20°C. All subsequent dilutions were made from these stocks and kept at 4°C.
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Batch Transfer Protocol
Amicrotitre plate reader measured optical densities every 20 min at 600nm as a proxy for pop-
ulation densities in different environments (R2>0.99, Fig S1 in S1 Text, section 1). 96-well
plates containing 150 μLof liquid per well incubated at 30°C were used to culture bacteria;
these were shaken in a linear manner before each measurement was taken.
For prolonged exposure to antibiotics, inoculating bacteria were taken from one colony and
cultured overnight in M9 minimal media (0.2% glucose, 0.1% casamino acids) at 30°C in a
shaker-incubator. At the end of each season, a 96-pin replicator sampled the liquid volume,
which was then transferred to a new plate containing fresh growth medium and antibiotics; the
same environment for each replicate population was maintained. Every subsequent transfer
was performed using the 96-pin replicator; the volume transferred was approximately 1.5μL.
OD time series were imported into Matlab R2013b to subtract the background (blank wells
containing only medium) and generate all other statistics.
Live Cell Counts
No claim is made on the basis of optical density data alone that a zero population density had
resulted from treatment. Zero densities were determined by observing an OD value below 10-2
units, whereafter the presence of cells was determined by spot tests. Serial dilutions were then
used to determine live cell numbers in colony-forming units, if any were detected (Fig S15 in
S1 Text, section 3).
WGSData Accession Number
Whole-genome sequence data with 18 samples and an annotated draft genome is available
from the European Nucleotide Archive (ENA) with study accession number PRJEB7832.
This data can be downloaded from http://www.ebi.ac.uk/ena/data/view/PRJEB7832.
Supporting Information
S1 Data. This file contains the data used to produce all figures in the main text.
(XLSX)
S2 Data. This file contains the data used to produce all figures in S1 Text.
(XLSX)
S1 Text. Supplemental information. Contains experimental materials and methods, typical
growth data and the rate of adaptation, additional data, a whole-genome sequencing analysis,
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S1 TEXT: USING A SEQUENTIAL REGIMEN TO ELIMINATE BACTERIA AT
SUB-LETHAL ANTIBIOTIC DOSAGES
Ayari Fuentes-Hernandez+, Jessica Plucain+, Fabio Gori+, Rafael Pena-Miller,
Carlos Reding, Gunther Jansen, Hinrich Schulenburg, Ivana Gudelj and Robert Beardmore⇤
§1 Experimental Materials and Methods
1.1 Media and strains.
All experiments were conducted using Escherichia coli K12(AG100) and M9 minimal media (0.2% glucose and
0.1% casamino acids). We used two antibiotics with a synergistic interaction: doxycycline (DOX) and erythromycin
(ERY). Stock solutions of antibiotics were made from powder stocks (Sigma-Aldrich) at 5mg/ml in water for DOX
and 100mg/ml in ethanol for ERY and stored at  20 C. All subsequent dilutions were made from these stocks and
kept at 4 C. After testing, no measurable decay in the e cacy of the antibiotic has been observed when storing these
antibiotics in either of these conditions for one week, or less.
1.2 Batch-transfer protocol
For all the protocols consisting of multiple serial batch transfers referred to in the main text, with each transfer
conducted once per ‘season’, we used the same microtitre plate reader (BioTek) to measure optical densities every 20
minutes at 600nm as a proxy for bacterial population densities in di↵erent environments (written as OD600nm or just
OD). We used 96-well plates containing 150µL of liquid in each well incubated at 30 C to culture bacteria, shaken in
a linear manner before each OD measurement was taken.
For an experiment exposing bacteria to antibiotics lasting several seasons (where each season lasts 12h or 24h) an
initial inoculation was performed using an isogenic population obtained from a single colony and cultured overnight
in M9 minimal media (0.2% glucose, 0.1% casamino acids) at 30  in a shaker-incubator. At the end of each season,
the same 96-pin plate replicator was used to sample the liquid volume (containing bacteria and spent medium) which
was then transferred to a new plate containing fresh growth medium and antibiotics, ensuring the same environment
for each replicate population was maintained. Every subsequent transfer to a fresh plate containing medium was
performed using the same 96-pin replicator, we estimated the volume transferred to be 1.5µL. The so-obtained, time-
dependent optical densities were then imported into Matlab in order to subtract the background (determined from
blank wells containing only medium) and compute the mean optical densities and other statistics.
N.B.: media-only wells testing for the presence of potential contamination were used on every 96-well microtitre plate.
If any showed turbidity above blank levels, the assay in question was repeated.
1.3 Live cell counts: optical density is a reasonable proxy for cell density
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Fig. S1 – Data showing that OD is positively correlated with a live cell count (CFU per ml) in the plate reading devices
that we use. (a) E. coli K12(AG100) was cultured in M9 and serially diluted to di↵erent OD values, these were then counted
to reveal CFU values (all error bars are 95% confidence intervals of the mean, three replicates). A linear regression (blue)
is shown next to data. A constrained linear regression that must pass through the datapoint (0, 0) is also shown (red). (b)
The latter indicates that OD has the potential to over-estimate live cell numbers at the lowest densities.
Many of the bacterial growth and inhibition experiments described in this article require the continual measurement
of bacterial population densities and this cannot be done with by-hand lab techniques, such as colony counting. We
therefore use devices for which proxies of population density can be rapidly produced using automated protocols that
read densities as light absorbance.
1
2 S1 TEXT: USING A SEQUENTIAL REGIMEN TO ELIMINATE BACTERIA AT SUB-LETHAL ANTIBIOTIC DOSAGES
No claim is made in the article on the basis of OD data alone that a zero population density has resulted under any
treatment conditions, the measurement error inherent to such devices is too great for that to be reliable. When any
claim is made that no cells are present, this is always deduced from first observing an OD600 value of below 10 2 units
after at least 12h growth, thereafter cells are counted manually following a spot test in order to determine whether
cells are present and, if so, how many. Fig. S1 shows that OD is a reasonable indicator of bacterial population density:
this measure correlates positively, and indeed linearly, with viable cell counts (measured in units of colony-forming
units per ml).
1.4 Dose-response curves
We determined dose-responses by measuring bacterial OD600nm dynamics at di↵erent dosages of both antibiotics,
the resulting growth data was used to estimate the drug concentration necessary to achieve x% inhibition with respect
to the null-antibiotic control (at drug concentrations hereafter denoted ICx). As illustrated inFig. S2, the approximate
IC50 values obtained for a 12h experiment were 0.04µg/ml for DOX and 6.13µg/ml for ERY. The degree of variation
in these measures is illustrated using a 95% confidence interval for each dose response curve in Fig. S2.
(a)













Hill fit ± CIs (R2 > 0.99, coeff ≈ 4.9)
12h observation ± s.e. (n = 4)
(b)















Hill fit ± CIs (R2 > 0.99, coeff ≈ 3.9)
12h observation ± s.e. (n = 4)
Fig. S2 – 12h dose-response curves for E.coli K12(AG100) for both drugs used in this study: (a) erythromycin and (b)
doxycycline. Superimposed Hill function datafits are used to estimate the value of, and error in, x when computing ICx
values, the shaded region represents an estimated 95% confidence interval, Hill coe cients are stated in the top-right corner
of each datatfit (4 replicates). Red lines denote the 95% confidence intervals of IC50 and IC70, as the lines do not intersect
estimates of both parameters are significantly di↵erent.
1.5 Drug interaction curves
We say that synergy is exhibited by a drug pair, at a given time, if the following holds. If B(t,D,E) denotes the
time-series of bacterial densities as a function of time and dose, given two drugs denoted D and E, then when
(1) B(t0, D0, 0) = B(t0, 0, E0) (an equi-potency assumption on both drugs)
(2) i(✓) := B(t0, ✓D0, (1   ✓)E0) < B(t0, 0, E0) for all ✓ between 0 and 1, (note the later equals B(t0, D0, 0) by
assumption)
the drugs D and E are said to synergise at basal dosages D0, E0 at time t0. Under these assumptions, by fitting a
quadratic to the interaction function i(✓), so that ↵✓2 +  ✓ +   ⇡ i(✓), we can determine the numerical degree of
synergy from the value of ↵. When the inequality ↵ > 0 holds for all E0, D0 and t0, a criterion that can be established
in practise using standard numerical fitting routines and a t-test, we then say D and E synergise. This procedure,
called the ↵-test, is detailed fully in [18]. The quadratic fits to bacterial density data in Fig. S3 establish that this
statistical test is passed for ERY, DOX in the experimental described conditions described above using the strain
E.coli K12(AG100).
1.6 The (n+ 1)-protocol: measuring collateral sensitivity and cross resistance
In order to quantify how acclimation (UK English equivalent ‘acclimatisation’) to one antibiotic impacts population
growth after a switch to another antibiotic occurs, and to measure this as a function of the duration of the acclimation
period, we evolved five replicates of an isogenic population of E. coli for n + 1 seasons at IC70 (see Fig. S4), where
each season lasts 24h, as follows.
Bacteria were exposed to a constant environment (DOX or ERY) for n   3 seasons before being transferred into
an environment containing the other drug: those growing in DOX were transferred into an environment containing
only ERY, those growing in ERY were then treated with DOX. We compared the optical densities of the population
that underwent a change in drug at the end of the n-th season to the corresponding optical density of the population
growing under constant conditions. This allows us to determine whether acclimation to one drug is associated with
increased sensitivity to the other.
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Fig. S3 – Establishing statistically significant synergy at both 12h and 24h using the ↵-test for synergy defined in [18]
(p-values indicated in the figure) with both erythromycin and doxycycline at their respective IC50 dosages. Superimposed
fits of a quadratic function is shown, the shaded region represents an estimated 95% confidence interval. The property that
the fit is a convex function (and not concave) establishes the ERY-DOX synergy because a 50-50 combination reduces the
optical density (indicated on the y-axis) relative to both ERY-only and DOX-only monotherapies.
(a)


































Hill fit ± CIs (R2 > 0.97, coeff ≈ 2.6)
24h observation ± s.e. (n = 4)
(b)


































Hill fit ± CIs (R2 > 0.97, coeff ≈ 4.7)
24h observation ± s.e. (n = 4)
Fig. S4 – 24h dose-response curves for E.coli K12(AG100) for both drugs used in the (n+ 1)-protocol: (a) erythromycin
and (b) doxycycline. (To ensure stationary phase occurred beyond 12h, the M9 medium was supplemented here with a three
times greater concentration of glucose thanFig. S2.)
The treatments implemented using the (n+ 1)-protocol are illustrated inFig. S5.
Fig. S5 – Treatments used in the (n + 1)-protocol. First, bacteria are grown under the e↵ect of a single-drug (ERY in
green and DOX in blue) for n days until a switch is performed and the other antibiotic is used for one day.
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1.7 The sequential deployment of antibiotics.
Di↵erences in population densities produced by di↵erent sequential treatments were measured as follows. An 8-
season batch transfer protocol was implemented, with each season having 12h duration. At the end of each season,
a 1% sample of the final population was transferred using a pin replicator into a fresh 96-well plate containing a
replenished environment (containing both fresh M9 media and antibiotic).
Drug treatments consisted of the sequential deployment of DOX and ERY whereby only one drug was used within
each season. The order in which the drugs were deployed defined each treatment and, in order to perform a like-with-
like comparison, we introduced the constraint that all treatments were balanced: by the end of an 8-season treatment,
each drug would be used for 4 seasons (ERY for 4, DOX for 4) and this is true for all treatments implemented. Thus,
these sequential treatments are illustrated using the schematic inFig. S6. Each such treatment was initially replicated
three times.
Fig. S6 – Sequential treatments and monotherapies implemented in an 8-season evolutionary assay (ERY in green, DOX
in blue). All treatments are balanced: they have an equal number of seasons for which each drug is deployed.
Di↵erent results are obtained in this protocol depending on the choices of dose for ERY and DOX. All treatments,
including monotherapies (ie. treatments that use one antibiotic for the entire duration), were implemented at IC50
and IC70 dosages. As a control, we also implemented the 50-50 combination treatments where, to clarify what this
means, if monotherapies used dosages of 3µg/ml for ERY and 0.1µg/ml of DOX, the 50-50 treatment would have
1
2 ⇥ 3µg/ml of ERY and 12 ⇥ 0.1µg/ml of DOX. By design, the 50-50 combination treatment must yield a lower OD
than the monotherapies in the first season to be consistent with previous studies reporting ERY and DOX (and our
prior data) as a synergistic drug pair [9, 18].
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§2 Typical growth data and the rate of adaptation
Typical raw data typical are shown in Fig. S7. If no drug is deployed (yellow data) the OD increases each day
with the bacterium entering stationary phase progressively earlier each transfer (a.k.a. season). Antibiotic use reduces
population growth and delays entry into stationary phase.
Fig. S7 – Mean optical density data (plotted as coloured areas) in an 8-season experiment with transfers performed every
12 hours. Each row represents a di↵erent treatment and the drug used each season is colour-coded (yellow areas represent
no drug, blue the use of DOX, green the deployment of ERY and red a 50-50 combination of DOX and ERY). Solid coloured
lines denote s.e., n = 5.
Calculating the phenotypic rates of adaptation using the measure defined in [9] for the data presented in Fig. S7
produces Fig. S8. This shows that growth rate adaption to treatment is di↵erent for each condition, being fastest
for the 50-50 antibiotic treatment and slowest for the DOX monotherapy. Interestingly, the rate of adaptation for
populations cultured in no-drug conditions are between these two extremes. This data shows that antibiotic inhibitory
e↵ect and the rate of adaptation are not necessarily correlated and that adaptation to a media-only environment (i.e.
no drug) can be just as rapid as adaptation to antibiotic-inhibited growth.
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Fig. S8 – (a) The rate of adaptation for each of the treatments shown in Fig. S7. There is a positive correlation between
rate of adaptation and final growth rate in the treated populations. The no-drug conditions produce higher growth rates
than the drug-treated conditions and adaptation is just as rapid as in drug-treated conditions. (b) Adaptation is fastest to
the synergistic 50-50 combination treatment. Importantly, the rate of adaptation to the no drug control environment is not
the lowest of all the conditions tested. This data indicates no positive correlation between rate of growth adaptation and the
inhibitory e↵ect of the antibiotics because adaptation can be just as fast in the absence, as in the presence, of antibiotics.
(c) Growth rate is, of course, greatest in the last season in the populations with no antibiotic. Moreover, growth rate is not
lowest on the last season in the 50-50 combination treatment, despite the ERY-DOX synergy (vertical bars are s.e., n = 6).
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§3 Additional Data
3.1 The combination treatment eventually loses out to all sequential treatments at IC50
The data presented in the figures of this section (Fig. S9, Fig. S10) demonstrate that a treatment producing
the greatest inhibitory e↵ect when measured over a single season need not continue to inhibit growth maximally as
treatment proceeds. At these dosages, the 50-50 combination treatment is optimal at reducing population growth in































Fig. S9 – Deviation in OD from the combination treatment at the end of each season for all sequential treatments tested.
Vertical thick black lines denote the mean OD of the 50-50 combination treatment, normalised and written as zero, vertical
dotted lines represent the mean OD taken over all the sequential treatments and the coloured dots show the deviation of the
OD of each sequential treatment from the 50-50 combination (blue dots: DOX, green dots: ERY). The histograms represent
the distributions of performances of all sequential treatments relative to the combination treatment in each season. This
series of so-called forest plots show how at the beginning of the experiment all dots are to the right-hand side of the 50-50 line:
their performance is worse than the multidrug combination. However, as the number of seasons increases, more treatments
cross the vertical line and thus achieve higher inhibition than the 50-50 combination. By the end of the experiment all
















Fig. S10 – A ‘Manhattan plot’ at IC50 dosages (3 replicates per treatment): ⌃OD(T) (on the y axis) denotes the
cumulative optical densities measured at the end of each season and these values are summed to produce a ‘skyscraper’ for
each treatment. Here T denotes 12h, the duration of each season, so OD(T) represents population density at the end of each
season. Vertical error bars are s.e., n = 3.
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3.2 No correlation between drug switching and inhibitory e↵ect at IC50 and IC70 dosages
We first determined the ODs produced by all the balanced sequential treatments at IC70 dosages and, as shown in
Fig. S11, we sought a negative correlation between the number of switches in an 8-season treatment and the number
of bacteria it produces. This was done in two ways: we measured the total number of bacteria produced by each
treatment (using OD as the proxy) and we measured the final OD produced, namely at 96h. We then compared the
number of drug switches with these population density measures produced by each treatment. This figure shows no
evidence of the correlation we sought.
(a)



















0 cells in 3 replicates
0 cells in 1 or 2 replicates
regression (R2 ≈ 0.00022, p ≈0.91)
(b)



















Fig. S11 – (a) At IC70 there is no correlation between the number of drug switches and the mean total number of bacteria
produced per sequential treatment. Here the 16 best performing IC70 treatments, those with lowest population densities at
96h in Figure 2A of the main text, are highlighted with red and black squares (error bars are s.e., n = 3). The black line is a
linear regression between the number of drug switches and the (cumulative) OD data, showing no evidence of a correlation.





















IC50 one−way anova p = 0.931




















IC50 one−way anova p = 0.992
Fig. S12 – H0: e↵ecting a change of drug correlates with a measurable change in OD. (a) This boxplot of relative change
in OD from one season to the next (namely (y x)/(x+ y) where x is OD at 12h on day n and y is OD at 12h on day n+1,
expressed as a percentage) provides no evidence to reject H0 using the same dataset as used inFig. S10. Here (y x)/(x+y)
(that, note, necessarily lies between  1 and +1) is computed for two treatment classes: ‘twist’ treatments occur when ERY
follows DOX or DOX follows ERY from day n to day n+1, ‘stick’ treatments occur when DOX follows DOX or ERY follows
ERY. (b) Stratifying the same treatments further is not su cient to reject H0.
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Fig. S13 – Sixteen di↵erent sequential ERY-DOX treatments were replicated at IC70 three times, each of these replicates is
compared with the zero-drug control (the former in one of three shades of red, the latter in yellow). In the 5 of these having
red squares in the legend, a spot test indicated no live cells in the growth medium after 96h of treatment. Of the remaining
11, in 4 there were no live cells found in 2 replicates and 7 treatments in which a single replicate had no live cells at 96h.
Thus, a total of 48 sequential treatments were trialled at sub-lethal dosages, 30 of which lead to complete elimination of
the bacterium by 96h. By way of contrast, and as expected, Fig. S14 shows that monotherapies and the 50-50 combination
treatment do not eliminate bacteria at these dosages. The drugs used for each treatment are indicated in each panel, with
a blue dot for DOX and a green dot for ERY.

















Fig. S14 – Monotherapies and 50-50 combination treatments at IC70 and the zero drug control, c.f. Fig. S13. This
illustrates the short-term synergy, the loss of synergy, it also highlights that these treatments lead to increasing population
densities at 96h (error bars are s.e. with n = 3).
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Fig. S15 – Dynamics of replicates of the sequential treatments at IC70 shown inFig. S13 that indicated a zero population
density in at least one replicate. These were replicated and cell densities counted each season, thus colony forming units
(CFUs) are now used on the y-axis (in fact, log10(1 + C) is shown where C is cell density measured in CFUs per ml which
is zero if C = 0.) The antibiotic treatments are indicated as a legend in each figure. Note how the population density of
one replicate can eventually collapse for a given treatment whilst a di↵erent replicate can recover, leading to large between-
replicate variations. Note also that this replicated dataset has 21 successful treatments from the full set of 48 replicates.
This is a di↵erent outcome to the first set of replicates shown in Fig. S13, however the so-called ‘red square’ treatments
behave consistently in all replicates by producing a zero CFU count at some time.
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§4 A whole genome sequencing analysis
In order to investigate antibiotic resistance adaptation based on prior and de novo mechanisms, we performed the
following analysis. We cultured bacteria with 12h seasons using a batch transfer protocol implemented in a shaken
flask with 5ml of M9 liquid medium, implementing one environmental condition without drugs (called the ‘no drug
control’) and two di↵erent antibiotic conditions. All were replicated three times. The two antibiotic treatments were
the 50-50 combination at IC50 dosages and the sequential treatment of the from ‘EDEDEDED’. Measuring a 150µL
sample from the flask in a plate reader at 600nm, the cumulative optical densities produced were similar for both
these drug treatments as shown inFig. S16. All replicate populations from 24h and 96h were then sequenced using the
paired end technology on a Illumina 7500 machine at the Exeter sequencing service. Both single-drug monotherapies
























Fig. S16 – Cumulative optical density at the end of each season for five di↵erent treatments: two single-drug treatments
(DOX in blue and ERY in green), a 50-50 multidrug combination (in red) and sequential treatment protocols based on a
daily antibiotic switch. Note how the treatment with the highest cumulative optical density is the 50-50 combination, despite
it being the most e↵ective drug at the beginning of the experiment. The label WGS indicates the densities and timings of
sequenced populations (3 replicates each).
4.1 Library preparation method
DNA was fragmented by sonication using a Biorupter for 30s on, 90s o↵, using low power for 10 minutes on ice.
Libraries were prepared using SPRIworks cartridges for Illumina (Beckman Coulter) and Nextflex indexed adapters,
with 300-600 bp size selection, amplified with 8 cycles PCR using Kapa HiFi DNA polymerase and purified using
GeneRead kit (Qiagen). Concentrations were determined using a Bioanalyser 7500 DNA chip. Libraries were pooled
in equimolar amounts, denatured, diluted to 6.5 pMol and clustered on a flowcell using a cBot (Illumina). 100 paired
end sequencing with a custom barcode read was completed on a HiSeq 2500 using Truseq SBS v3 reagents (Illumina).
4.2 Construction of a Local Reference
To facilitate the genomic analysis we first constructed a local reference genome of E. coli K12 (AG100), constructed
by modifying the publicly available annotated genome of strain MG16551 [19]. This choice was motivated by its close
relation with AG100 and the quality of the existing annotation.
Reads were processed with fastq-mcf [2] to remove adapters from the sequencing data and to trim and filter low-
quality reads. In particular, cycles with at least 1% of ‘N’s were removed (command-line parameter: -x 0.01). The
remaining reads were mapped to MG1655 using the Burrows-Wheeler aligner BWA [13] with standard parameters. The
resulting alignments were processed with Samtools 1.0 [14], with pair/trio calling enabled (command-line parameter:
-T). Subsequently, alignments were sorted, artifacts and duplicates were removed, and finally the alignments was
indexed. Unaligned reads were stored separately.
Structural Variations (SVs) were detected using Pindel [25]. Its pattern-growth algorithm detects breakpoints of
large deletions and medium-sized insertions by identifying paired reads for which only one of the reads can be mapped
to the reference. It then attempts to break the unmapped read into two and maps both shorter fragments to the
reference. If successful, the breakpoints of deletions or insertions can thus be determined. We restricted the detection
to SVs of maximum 2,071,552bp (command-line parameter: -x 8). The detected SVs were visually inspected with
IGV [21, 23]. We validated 5 deleted regions, 9 putative breakpoints and 9 indels, nucleotide polymorphisms were
intentionally ignored at this step.
1MG1655 genome and its annotation files are available at ftp://ftp.ncbi.nih.gov/genomes/Bacteria/Escherichia_coli_K_12_
substr__MG1655_uid57779/; version NC 000913.2 of 22 July 20013 was used.
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Using a Python script, we removed deleted regions and putative breakpoints detected by Pindel, resulting in a set
of 15 non-overlapping sequences free of major SVs. Detected indels were subsequently applied to these sequences.
With Samtools we extracted the reads previously mapped to removed regions or within 2/3 of the library insert size
from their borders. These and the reads without a feasible alignment were assembled with Velvet [26] resulting in
a set of contigs. The union of this set and the set of the 15 sequences was used to generate a set of sca↵olds using
SSPACE [3]. This software uses the distance information of paired-ends to assess the order, distance and orientation
of the submitted contigs and combines them into sca↵olds. The resulting sca↵olds were extended with GAPFILLER
[4] that attempts to close gaps between sca↵olds using the distance information of paired-read data; 21,942 sca↵olds
were thus obtained.
These sca↵olds were aligned to MG1655 using Mauve [20]. This software can align a set of sequences to one genome
from a related one that di↵ers from the former for the presence of SVs and only the 13 longest sequences (the shortest
was 109,280 bp) could be aligned to the reference. The remaining sequences, not more than 2,375 bp each, were
discarded. The 13 sca↵olds were concatenated into one sequence, here called the ‘intermediate’ reference according to
an order and orientation given by Mauve.
We used Pindel to verify if SVs were still present in the intermediate reference and to validate the multiple nu-
cleotide polymorphisms detected in the previous execution of Pindel. No SV was observed visually with IGV, while 6
polymorphisms of 2 consecutive nucleotides each, detected even before by Pindel, were still present. We applied these
polymorphisms to the intermediate reference using the script vcf-consensus of the vcf-tools utility [6]. Finally, SNPs
were detected using the software VarScan.
VarScan uses both heuristic and statistical methods to call SNPs based on read depth, base quality, significance
and variant frequency. We used VarScan with the following parameters: p-value threshold of 0.05 for calling variants,
minimum read depth of 20 to make a call at a position, at least 8 supporting reads at a position to call variants,
base quality not less than 20 at a position to count a read, minimum variant allele frequency of 0.03; frequency
to call homozygote of at least 0.9 (command-line parameters: --p-value 0.05 --min-coverage 20 --min-reads2
8 --min-avg-qual 20 --min-var-freq 0.03 --min-freq-for-hom 0.9) The detected SNPs were applied to the
intermediate reference with vcf-consensus and the resulting sequence was our local reference. The local reference was
mostly annotated using RATT [17], transferring the annotation from MG1655 to this sequence for regions with high
synteny. Using the RAST annotation server, we annotated the two longest regions with low synteny (37,193 bp and
7,166 bp, respectively).
4.3 Mapping onto local reference
All 18 replicates of three drug treatments were mapped to the local AG100 reference genome using the same method
adopted for mapping the control replicate to the MG1655. As above, reads were processed with fastq-mcf and mapped
to the local reference with BWA. Again, SNPs and SVs were called with VarScan and Pindel, respectively, using the
same parameters previously adopted. Additionally, we used CNVnator [1] to discover copy number variations (CNVs).
This software detects CNVs through an analysis of read mapping density (coverage) within di↵erent bins along the
genome. A bin size of 60 was chosen for all CNVnator analyses.
4.4 SNP-detection heuristic
Let ‘0’ denote a known wild-type allele at a given locus and suppose that Illumina sequencing produces n aligned
reads covering this locus that is denoted by a sequence of alleles, {Xj}nj=1, where each Xj is a Bernoulli random value
that only takes the values ‘0’ or ‘1’, the latter symbol (taking a numerical of unity) denoting any synonymous or




j=1Xj . Suppose that the systemic per-nucleotide error rate at each
locus is ✏, this is the probability that one Illumina read reports an incorrect allele following alignment.
A putative SNP acceptance rate of ↵ per read (expressed as a value between 0 and 1) is here said to produce a
false positive rate p that is defined to be the probability that n aligned reads reports at least ↵⇥n occurrences of the
allele ‘1’ due to Illumina read error. This is the value p := P(nYn > n↵) = P(Yn > ↵). As each Xj can be modelled as
a Bernoulli trial with parameter ✏, for su ciently large n the probability distribution of Yn can be approximated by
a normal distribution with the following mean and variance parameters (following standard notation) µ := E(Yn) = ✏
and  2 := var(Yn) = ✏(1  ✏)/n. Thus
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where ↵ > ✏. Using a value ✏ = 10 2 [16, 15] and a mean observed value for coverage of n ⇡ 200 (this is representative
of values given in Fig. S17), with this calculation, shows a putative variant frequency of ↵ = 2% yields the value
p ⇡ 0.0776 whereas using ↵ = 3% yields p ⇡ 2.24 ⇥ 10 3. The requirement that p < 0.05 thus permits us only to
report SNPs with an estimated frequency of 3% or greater.
4.5 WGS Results
Our analysis indicated a 412,380bp duplication (from 273,601 to 685,980) in all 6 drug treatment replicates at 96h.
After a list of putative SNPs was first generated in the manner detailed above, Table S1,Table S3 and Table S4 then
summarise only those SNPs for which significant longitudinal or between-treatment di↵erences are observed using a
one or two-way anova with a threshold of p < 0.1. Putative SNPs that do not pass this acceptance criterion have not
been reported. Genes annotated using red font are contained within the duplicated region. For completeness, Table
S5 contains basic statistics used in the whole-genome analysis.
(a) (b)
Fig. S17 – (a) Mean coverage (three replicates) of the di↵erent drug-treated and drug-free sequenced populations, ± s.e.,
n = 3. (b) Evidence for a duplicated genomic region given by the ratio of mean coverage in two contiguous regions: inside
and outside addresses 273,601bp to 685,980bp. There is no evidence of the duplication (where this ratio equals 2) in the
absence of drug treatment, but there is evidence that it is duplicated in all drug-treated populations by 96h. The indicates
p-values are for t-tests seeking di↵erences in mean coverage between 24h and 96h.
Comments regarding SNPs:
(1) The Ribosomal Mutation Database filtered by position for ‘595’ (http://goo.gl/sbFIFd) only shows 16S
(not 23S) SNPs in this location. The database indicates that none of the rrn SNPs in Table S1 are known
tetracycline or erythromycin resistance mutations.
23S erythromycin resistance mutations in the database: http://goo.gl/f7WrCH
The database has a tetracycline resistance mutation but we do not observe it here: http://goo.gl/0NsnJf
(2) atoB is a short-chain fatty acid degradation enzyme (thiolase II) [11] in the ato operon.
(3) tauA is required for sulphur utilisation ‘expressed only under conditions of sulfate or cysteine starvation’ [7];
cysteine is an ↵-amino acid in the casamino acids supplied at 0.1%.
(4) mdtG (yceE) is a putative e✏ux protein that confers resistance to fosfomycin and deoxycholate, also the
quinolone norfloxacin (see http://goo.gl/9pLxZ1), it is a member of the marA-soxS-rob stress regulon that
mediates expression of the acrAB-tolC pump [8].
(5) yqhC regulates yqhD where the latter is ‘a scavenger of toxic aldehydes produced by lipid peroxidation’ [10] (see
also ‘we propose that YqhC is a transcriptional activator of YqhD, which acts as an aldehyde reductase’ [12]),
as does paoC of Table S3.
(6) ubiD catalyses the synthesis of the antioxidant ubiquinone (http://goo.gl/2Al4fS) that ‘can prevent or
control chain lipid peroxidation in biomembranes’ [5].
(7) slt ‘degrades the murein polymer of the bacterial cell wall to 1,6-anhydromuropeptides’ [22].
(8) E.coli prophage (including DLP12) can aid survival in ‘adverse environments’ including osmotic, oxidative
and acid stresses [24].
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4.6 Tables of SNPs (Table S1,Table S3 andTable S4)
These summarise significant SNPs observed at 24h and 96h under the di↵erent treatment conditions. The mean
frequency in the populations where the SNP was detected is indicated and a superscript denotes the number of
replicates in which the SNP was observed. A blank entry denotes it was not detected.
Table S1 – Ribosomal SNPs: all belong to 23S.
% mean variant frequency(replicates, if not all)
50%-50% Dox/Ery Control
operon position relative posn 24h 96h 24h 96h 24h 96h
rrnH 226,521 595 5(2)
227,791 1,865 3(1) 17
rrnG 2,723,624 1,865 3(1) 9
2,724,894 595 8
rrnD 3,421,431 1,865 4(1) 13
3,422,701 595 8
rrnC 3,940,810 595 4(1) 17
rrnA 4,034,586 555 7
rrnB 4,165,708 595 4(1) 8
4,166,978 1,865 10
rrnE 4,207,110 595 3(1) 9
4,208,380 1,865 5(1) 7
Table S2 contains a list of genes within the duplicated genomic region that are known to interact with antibiotics
in some way, whether through drug binding or e✏ux, or else are implicated in the regulation of stress pathways that
may be associated with increased resistance.
Table S2 – Several antibiotic-binding and resistance genes are found in the duplicated genomic region, including their
annotations. note (1): emrE provides resistance against positively charged compounds including ethidium bromide and
erythromycin; note (2): nfsB reduces a broad range of nitroaromatic compounds, including antibiotics nitrofurazone and
nitrofurantoin.
start pos end pos. gene annotation
394,429 b.p. 395,586 b.p. ampH penicillin-binding protein
395,938 397,158 sbmA peptide antibiotic transporter
444,601 445,965 yajR YajR MFS transporter
451,369 452,844 ampG muropeptide transporter
458,187 460,541 lon DNA-binding ATP-dependent protease La
468,170 469,942 mdlA predicted multidrug transporter subunit; ATP-binding component
469,935 471,716 mdlB fused predicted multidrug transporter; ATP-binding components
480,553 483,702 acrB multidrug e✏ux system
483,725 484,918 acrA multidrug e✏ux system
485,060 485,707 acrR regulates the acrAB operon
502,775 503,995 fsr fosmidomycin e✏ux transporter
515,882 516,661 ybbM putative transport; drug/analog sensitivity
567,614 567,946 emrE member of the SMR family of transporters (see note (1))
592,541 593,914 cusC copper/silver e✏ux system, outer membrane component
594,420 595,643 cusB copper/silver e✏ux transport system - membrane fusion protein
595,655 598,798 cusA copper/silver e✏ux system, membrane component
601,712 602,416 nfsB oxygen-insensitive NAD(P)H nitroreductase (see note (2))
659,693 660,976 dacA penicillin-binding protein
662,142 663,254 mrdB rod shape-determining membrane protein







































































Table S3 – SNPs located neither in prophage nor ribosomal genes.
% mean variant frequency(replicates, if not all)
50%-50% Dox/Ery Control
gene position 24h 96h 24h 96h 24h 96h annotation
ampE 119,553 b.p. 8(2) 6(1) 6(1) 13(1) regulator; ampicillin resistance inner membrane protein
duplicated region (red text denotes duplicated genes)
paoC 298,353 9(1) 7(2) 5(2) aldehyde oxidoreductase, moco-containing subunit
tauA 384,897 19(1) 68 taurine transport system periplasmic protein
ybbJ 513,924 4(2) inner membrane protein, stimulates mutant suppression
mdtG 1,157,546 21 24 25 19 17(1) 24 multidrug resistance e✏ux transporter
atoB 2,329,327 8(1) 7(1) 8 9(1) acetyl-CoA acetyltransferase
yqhC 3,151,384 45 putative ARAC-type regulatory protein
rng 3,394,063 6(2) endoribonuclease involved in 16S rRNA processing
ubiD 4,022,772 20(1) 10(2) 3-octaprenyl-4-hydroxybenzoate decarboxylase
rhaM 4,089,608 8(2) 7(2) 9(1) 7(2) 7(2) L-rhamnose mutarotase
slt 4,628,265 9(1) 10 7(1) 9 6(1) 11 soluble lytic murein transglycosylase
Table S4 – Prophage-related SNPs.
% mean variant frequency(replicates, if not all)
50%-50% Dox/Ery Control
gene position 24h 96h 24h 96h 24h 96h annotation
ybcV 576,213 b.p. 37(2) 58(1) 35(1) 41(1) DUF1398 family protein
ybcW 576,962 47 64 49 68 48 51 phage or prophage related, unclear function
ylcI 577,244 51 68 52 69 49 52 DUF3950 family protein
rzoD 577,639 9 3 9(2) 5(2) 11(2) 7 DLP12 prophage protein
rzpD 577,772 14 20(2) 12(1) 17 17 over-expression causes abnormal biofilm architecture (prophage DLP12)
nohD 577,984 54 37 49 36 50 55 DNA packaging (DLP12 prophage protein)
nohQ 1,639,729 14 8 12 9 13 10 DNA packaging
ydfJ 1,640,037 49 46 45 42 45 42 prophage related, putative transport protein
insH1 3,126,511 7(1) 7(1) 10(1) 9(1) transposon related
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Table S5 – Basic statistics for Illumina reads: statistics of the reads averaged over 3 replicates.
(a)
DOX/ERY sequential mean (st. error)
24h 96h
Number of reads 13,289k (1,161k) 15,028k (429k)
Read max length 99.0 (0.0) 99.0 (0.0)
Read mean length 74.2 (0.8) 74.2 (0.8)
Read min length 15.0 (0.0) 15.0 (0.0)
Mapped reads (%) 98.8 (0.2) 99.3 (0.1)
Mean Mapping Quality 58.8 (0.01) 58.8 (0.0)
(b)
50-50% combination mean (st. error)
24h 96h
Number of reads 11,420k (669k) 15,831k (821k)
Read max length 99.0 (0.0) 99.0 (0.0)
Read mean length 73.3 (0.8) 74.3 (0.8)
Read min length 15.0 (0.0) 15.0 (0.0)
Mapped reads (%) 99.5 (0.03) 99.2 (0.1)
Mean Mapping Quality 58.8 (0.01) 58.8 (0.0)
(c)
No-drug control mean (st. error)
24h 96h
Number of reads 11,691k (3,091k) 13,249k (552k)
Read max length 99.0 (0.0) 99.3 (0.3)
Read mean length 71.1 (0.9) 75.3 (0.07)
Read min length 15.0 (0.0) 15.0 (0.0)
Mapped reads (%) 96.6 (0.4) 98.5 (0.04)
Mean Mapping Quality 58.8 (0.01) 58.8 (0.0)
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§5 An Additional Simulation of the Mathematical Model
The mathematical model featured in the main text and implemented using the parameter values in TableS6 shows
that an asymmetric collateral sensitivity between ERY and DOX can arise for the following reason. The e✏ux pump
is predicted to have di↵erent a nities for ERY and DOX, this causes di↵erent rates of selection for cells that express
the pump and, also, for cells that duplicate the pump. This means di↵erent population structures are supported by
the use of either drug in monotherapy.
To show this can be the basis of an ACS using the model, we first choose antibiotic supply concentrations for both
drugs at their IC50 (measured at 24h) in the model (main text, third column in Fig. 5A). This same figure from the
main text then shows that the population of bacteria adapts during five days of treatment with ERY, with increases
in the number of cells both expressing the e✏ux pump and having duplications of the pump genes.
In the mutation-selection equilibrium indicated by this figure, the population converges to a stable configuration
with population densities below ones that are achieved under no drug conditions. However, a switch to DOX in the
model sees a change in the relative frequency of pump duplications but, for instance, because the pump in the model
has di↵erent e ciencies at removing the two drugs from within the cell, this exchange in drug sees population densities
rapidly increase. In the figure, after the switch the population soon achieves densities close to those observed without
the drug. The third column, bottom plot of Fig. 5A and then Fig. 5B show analogous, but opposite, e↵ects when the
drugs are exchanged in the opposite sense.
Thus there are a number of factors that can contribute to an asymmetric collateral sensitivity: di↵erent e ciencies
of the pumps at e✏uxing the drugs, the di↵erent a nities of the drug for their targets, the di↵erent reductions in
absolute fitness attributable to each drug, the mutation rates associated with the duplications and the selection for
each of those mutations resulting from these factors that control the rate of sweep of the duplications. Given such
physical and evolutionary asymmetries, the model exhibits both a cross resistance and a collateral sensitivity, as the
terms are defined in the text.
Fig. S18 shows that the population densities produced by each treatment depends, even in this theoretical model, on
the way in which drugs are sequenced. Although both drugs are calibrated in the figure to an IC50 dose with respect to
a population consisting almost of entirely of wild-type cells that do not carry duplications of the pump, as treatments
progress the population structures do change. This can mean, as inFig. S18, that some sequential treatments produce
more bacteria than the 50-50 combination, whereas some produce fewer. Indeed, of the treatments shown inFig. S18,















Fig. S18 – A Manhattan plot computed using the theoretical model from the main text as determined at IC50 dosages. Note
how the sequential treatments (here of four seasons’ duration) can be either better, or worse, than the 50-50 combination
treatment depending on the orders in which the drugs are switched. Note the sequential treatment that produces fewest
cells of all is the unbalanced ‘DEEE’ treatment.
Remark 1. The parameter values given in Table S6 give rise to optical densities in the mathematical model (at 0.2%
glucose) that are substantially larger than those reported in the experimental data throughout this article. This is not
an error, rather the stated parameters were determined by calibrating the mathematical model in the main text against
optical density data read at 600nm in 384 well plates [18]. With similar liquid volumes as the 96 well plates we use here,
the path length taken for the absorbance measurement is necessarily larger and, therefore, similar population densities
will result in very di↵erent optical densities between that article and this. Therefore, an optical density conversion
factor of approximately 14OD units is required to compare data from this article and the mathematical model defined
in [18] that we use here.
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Table S6 – All parameters used in the mathematical model are defined in [18, Supplementary Information]. Units
are defined as follows: [S0] = [E0] = [D0] = µg/ml, [c] =OD/µg, [V ] = µg/OD/h, [K] = µg/ml, [e] = [d] =
ml/µg, [ed] = (ml/µg)
2, [ve] = [vd] = ml/OD/h, [ke] = [kd] = dimensionless, ['e] = ['d] = ml/OD/h, [ ] = per
genome/h, [ ] = dimensionless = [g], [dD] = [dE ] = per day.
Description Parameters Value (source [18])
glucose supply at 0.2% S0 2,000
antibiotic supply (model IC50 @ 24h) for (ERY,DOX) (E0, D0) (13,0.138)
growth kinetics (c, V,K) (0.000315,1140,0.54)
inhibitory responses to antibiotics (e,d,ed) (0.2, 300, 4,000)
antibiotic uptake and e✏ux kinetics (ERY) (ve, ke, e) (4000, 19.7, 93.1)
antibiotic uptake and e✏ux kinetics (DOX) (vd, kd, d) (4000,0.8,0.041)
duplication rate, Poisson loss rate ( , ) (10 4,18)
drug decay parameters dD, dE in the interval [
1
24 ln(0.8), 0]
diminishing rate of returns of new pumps per duplication g 0.5
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